

# **Antimicrobial prescribing in 3 public hospitals of rural** South-Africa in 2023: results from the global point prevalence survey





Joanna Gallay<sup>1</sup>, Jacques D. du Toit<sup>2,3,4</sup>, Friederike Konik<sup>5</sup>, Lea Albrecht<sup>5</sup>, Marco Böhler<sup>5</sup>, Ann Versporten<sup>6</sup>, Ines Pauwels<sup>6</sup>, Annelies Boven<sup>7</sup>, Erika Vlieghe<sup>7,8</sup>, Noémie Boillat-Blanco<sup>1</sup>

**Contact:** joanna.gallay@unil.ch

<sup>1</sup>Infectious Diseases Service, University Hospital of Lausanne, Switzerland; <sup>2</sup>MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public Health, University of the Witwatersrand, South Africa; <sup>3</sup>Swiss Tropical and Public Health Institute, Allschwil, Switzerland; <sup>4</sup>University of Basel, Basel, Switzerland; <sup>5</sup>University of Groningen, Netherlands; <sup>6</sup>Laboratory of Medical Microbiology, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium; <sup>7</sup>Global Health Institute, University of Antwerp, Antwerp, Belgium; <sup>8</sup>Department of General Internal Medicine, Infectious Diseases and Tropical Medicine, University Hospital Antwerp, Antwerp, Belgium



## **BACKGROUND & OBJECTIVES**

- In low- and middle-income countries, especially in rural settings, local evidence-based guidelines and resistance patterns at the hospital level are often lacking, impairing the optimal use of antibiotics
- We aimed at identifying targets for antimicrobial stewardship activities in 3 hospitals in rural South Africa

## **METHODS**

- The Global-PPS, a standardized surveillance method to measure antimicrobial prescribing and resistance (www.global-pps.com), was conducted in February 2023 in 3 public hospitals of rural North Mpumalanga province (hospital 1: 269 beds, hosp 2: 425 beds, hosp 3: 178 beds)
- All inpatients receiving an antimicrobial on the day of the survey were included

7%

10%

13%

6%

## RESULTS

55% female **289** inpatients 45% male were surveyed



Age distribution  $\leq$  12 (neonates and

paediatrics) **13-49** years

■ ≥50 years

55% inpatients received at least one systemic antimicrobial the day of survey

100%

90%

80%

70%

60%

50%

40%

**30**%

20%

10%

0%

**Type of indication for** prescribing antibiotics Community acquired infections Healthcare associated infections 54% Surgical prophylaxis Medical prophylaxis Unknown indications

## Antimicrobial prescription prevalence by wards

| Adult wards<br>(N=207) |         |           |          |               | Paediatrics<br>(N=51) |         | Neonatal<br>(N=31) |        |   |
|------------------------|---------|-----------|----------|---------------|-----------------------|---------|--------------------|--------|---|
|                        | Medical | Isolation | Surgical | Gyn-<br>obst* | ICU                   | Medical | Surgical           |        |   |
| Hosp 1                 | 38%     | 100%      | 80%      | 44%           |                       | 38%     | 0%                 | 25%    | F |
|                        | (14/37) | (2/2)     | (8/10)   | (10/23)       | -                     | (3/8)   | (0/5)              | (4/16) | ļ |
| Hosp 2                 | 65 %    | 100%      | 65%      | 46%           | 100%                  | 77%     |                    | 63%    | 1 |
|                        | (17/26) | (6/6)     | (24/37)  | (13/28)       | (2/2)                 | (13/17) |                    | (5/8)  |   |

## Systemic antibiotics used according to WHO AWaRe **Classification for most frequent indications**

| Hosp 3 | 70%<br>(19/27) | -    | 44%<br>(4/9) | -   | -    | 81%<br>(17/21) |    | 43%<br>(3/7) |
|--------|----------------|------|--------------|-----|------|----------------|----|--------------|
| Total  | 56%            | 100% | 64%          | 45% | 100% | 72%            | 0% | 39%          |

\*gynecology-obstetrics (medical and surgical)

## Systemic antibiotics used for most frequent indications



| Most prescribed systemic<br>antibiotics and guideline<br>compliance |                                       |  |                          |  |  |  |
|---|---------------------------------------|--|--------------------------|--|--|--|
|   | Prevalence<br>(% of<br>prescriptions) | As per<br>guidelines*<br>(% of<br>prescriptions) | 80%<br>70%<br>60%<br>50% |  |  |  |
| Ceftriaxone   | 23.8%                                 | 49.2%  | 40%                      |  |  |  |
| Metronidazole   | 18.5%                                 | 17.4%  | 30%                      |  |  |  |
| Co-amoxicillin  | 14.1%                                 | 28.6%  | 20%                      |  |  |  |
| *when diagnosis was known, and guidelines were 0%<br>available      |                                       |  |                          |  |  |  |

Skin and soft Unknown Central Surgical Lower prophylaxis tissue respiratory nervous system infections tract infections infections Watch 📕 Reserve Access

## **Quality indicators for systemic antibiotic** prescriptions for most frequent indications



#### **Other key findings:**

- While 14.9% of the prescriptions were for surgical prophylaxis, 94.6% of those were prescribed for more than one day
- A diagnosis was documented for 84.7% of the prescriptions and 53.1% of the prescriptions were compliant to national guidelines

## CONCLUSION

- Half of inpatients in this rural region were receiving antibiotics on the day of survey, which is higher than previous reports in South-Africa of 33.6%<sup>1</sup>
- Potential targets for antimicrobial stewardship interventions are high use of Watch antibiotics, prolonged use of antibiotics for surgical prophylaxis and inappropriate prescribing of metronidazole
- Documentation of diagnosis and treatment duration in patient records should be improved to reliably assess treatment appropriateness
- Global-PPS will be useful to evaluate antimicrobial stewardship interventions and trends in antibiotics prescriptions
  - 1. PP Skosana et al. 2021: A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications, Expert Review of Anti-infective Therapy, 19:10

Disclosures: bioMérieux is the sole industrial partner of the Global-PPS. The company has no role in study design, data collection, data analysis, data interpretation, or writing the report. Data are strictly confidential and stored anonymously at the coordinating centre of the University of Antwerp.